Lung cancer

Alesha A Thai; Benjamin J Solomon; Lecia V Sequist; Justin F Gainor; Rebecca S Heist

doi:10.1016/S0140-6736(21)00312-3

Lung cancer

Lancet. 2021 Aug 7;398(10299):535-554. doi: 10.1016/S0140-6736(21)00312-3. Epub 2021 Jul 21.

Authors

Alesha A Thai¹, Benjamin J Solomon¹, Lecia V Sequist², Justin F Gainor², Rebecca S Heist³

Affiliations

¹ Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC, Australia.
² Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
³ Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. Electronic address: rheist@partners.org.

PMID: 34273294
DOI: 10.1016/S0140-6736(21)00312-3

Abstract

Lung cancer is one of the most frequently diagnosed cancers and the leading cause of cancer-related deaths worldwide with an estimated 2 million new cases and 1·76 million deaths per year. Substantial improvements in our understanding of disease biology, application of predictive biomarkers, and refinements in treatment have led to remarkable progress in the past two decades and transformed outcomes for many patients. This seminar provides an overview of advances in the screening, diagnosis, and treatment of non-small-cell lung cancer and small-cell lung cancer, with a particular focus on targeted therapies and immune checkpoint inhibitors.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Carcinoma, Non-Small-Cell Lung / diagnosis*
Carcinoma, Non-Small-Cell Lung / therapy*
Humans
Lung Neoplasms / diagnosis*
Lung Neoplasms / therapy*
Small Cell Lung Carcinoma / diagnosis*
Small Cell Lung Carcinoma / therapy*